Alesia Sadosky1, Jack Mardekian2, Bruce Parsons2, Markay Hopps2, E Jay Bienen3, John Markman4. 1. Pfizer, Inc., New York, NY, USA. Electronic address: alesia.sadosky@pfizer.com. 2. Pfizer, Inc., New York, NY, USA. 3. Outcomes Research Consultant, New York, NY, USA. 4. Translational Pain Research Program, Department of Neurosurgery, University of Rochester Medical Center, Rochester, NY, USA.
Abstract
AIMS: Diabetic peripheral neuropathy (DPN) accompanied by painful symptoms is known as painful DPN (pDPN). This study characterized healthcare resource utilization and costs in patients with DPN, pDPN, and severe pDPN relative to diabetes only. METHODS: Four adult cohorts were identified from the Humedica database: type 2 diabetes without DPN (n=288,328); DPN (n=35,050); pDPN (DPN subjects with a pain score ≥1 on a 0-10 numeric rating scale; n=3449); and severe pDPN (pain scores 7-10; n=1824). Resource utilization and costs for 12-months post-diagnosis were compared for diabetes relative to the other cohorts. RESULTS: Demographic characteristics were different across cohorts. Relative to diabetes alone, DPN, pDPN, and severe pDPN were characterized by significantly higher proportions of patients with resource utilization for all resource categories (all P<0.0001); the highest resource use generally observed for severe pDPN. Total annual direct medical costs were $6632 for diabetes only, with costs for DPN ($12,492), pDPN ($27,931), and severe pDPN ($30,755) significantly higher (all P<0.0001); outpatient costs were consistently the primary driver of total costs. CONCLUSIONS: Patients with DPN, pDPN, and severe pDPN had significantly greater healthcare resource utilization and costs than patients with diabetes only, with the highest burden associated with severe pDPN.
AIMS: Diabetic peripheral neuropathy (DPN) accompanied by painful symptoms is known as painful DPN (pDPN). This study characterized healthcare resource utilization and costs in patients with DPN, pDPN, and severe pDPN relative to diabetes only. METHODS: Four adult cohorts were identified from the Humedica database: type 2 diabetes without DPN (n=288,328); DPN (n=35,050); pDPN (DPN subjects with a pain score ≥1 on a 0-10 numeric rating scale; n=3449); and severe pDPN (pain scores 7-10; n=1824). Resource utilization and costs for 12-months post-diagnosis were compared for diabetes relative to the other cohorts. RESULTS: Demographic characteristics were different across cohorts. Relative to diabetes alone, DPN, pDPN, and severe pDPN were characterized by significantly higher proportions of patients with resource utilization for all resource categories (all P<0.0001); the highest resource use generally observed for severe pDPN. Total annual direct medical costs were $6632 for diabetes only, with costs for DPN ($12,492), pDPN ($27,931), and severe pDPN ($30,755) significantly higher (all P<0.0001); outpatient costs were consistently the primary driver of total costs. CONCLUSIONS:Patients with DPN, pDPN, and severe pDPN had significantly greater healthcare resource utilization and costs than patients with diabetes only, with the highest burden associated with severe pDPN.
Authors: Christine Miaskowski; Judy Mastick; Steven M Paul; Kimberly Topp; Betty Smoot; Gary Abrams; Lee-May Chen; Kord M Kober; Yvette P Conley; Margaret Chesney; Kay Bolla; Grace Mausisa; Melissa Mazor; Melisa Wong; Mark Schumacher; Jon D Levine Journal: J Pain Symptom Manage Date: 2017-01-04 Impact factor: 3.612
Authors: Chaoling Dong; E Scott Helton; Ping Zhou; Xuan Ouyang; Xavier d'Anglemont de Tassigny; Alberto Pascual; José López-Barneo; Eroboghene E Ubogu Journal: Tissue Barriers Date: 2018-09-05
Authors: Kord M Kober; Melissa Mazor; Gary Abrams; Adam Olshen; Yvette P Conley; Marilyn Hammer; Mark Schumacher; Margaret Chesney; Betty Smoot; Judy Mastick; Steven M Paul; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2018-08-30 Impact factor: 3.612
Authors: Barbara H Braffett; Rose A Gubitosi-Klug; James W Albers; Eva L Feldman; Catherine L Martin; Neil H White; Trevor J Orchard; Maria Lopes-Virella; John M Lachin; Rodica Pop-Busui Journal: Diabetes Date: 2020-02-12 Impact factor: 9.461